FINWIRES · TerminalLIVE
FINWIRES

華東医薬の帰属利益は2025年に2.8%減少する見込み

-- 華東医薬(SHE:000963)の2025年の帰属利益は、前年同期比2.8%減の34億1000万元となる見込みであることが、金曜日に上海証券取引所に提出された書類で明らかになった。 営業収益は前年同期比4.1%増の436億元となった。 株価は金曜日の午後の取引で3%上昇した。

Related Articles

Asia

Resolute Mining Says BlackRock Group Reduces Stake

Resolute Mining (ASX:RSG) received notice that BlackRock Group and its subsidiaries decreased their holdings in the company to 5.08% from 6.2%, according to a Monday filing with the Australian bourse.BlackRock Group now owns 108.7 million shares in the company, the filing said.

$ASX:RSG
Asia

Alkane Resources' March Quarter Production Beat Driven by Higher-Than-Modeled Head Grades, Euroz Hartleys Says

Alkane Resources (ASX:ALK) delivered a material production beat in the March quarter, driven mainly by higher-than-modeled head grades across its operations, a small beat on throughput at its Tomingley gold project in New South Wales, as well as higher recoveries at the Bjorkdal gold mine in Sweden, Euroz Hartleys said in an April 24 note.The company reported consolidated production of abut 45,800 ounces of gold equivalent, an early group record, Euroz Hartleys said.The equity research firm noted that Alkane Resources remains debt-free with the exception of AU$20 million in equipment financing, while the execution of an undrawn AU$110 million revolving facility and a AU$40 million contingent instrument facility provides liquidity to act fast on emerging opportunities.The company is on track to surpass the midpoint of fiscal 2026 guidance of 160,000 to 175,000 ounces of gold equivalent production at all-in sustaining costs of AU$2,600 to AU$2,900 per ounce. However, Euroz Hartleys expects softer quarter-over-quarter production in the three months through June due to lower head grades across the group.Euroz Hartleys kept a buy rating on the company while adjusting its price target to AU$2.53 from AU$2.50.

$ASX:ALK
Asia

Nextdc Launches AU$500 Million Retail Entitlement Offer

Nextdc (ASX:NXT) opened the retail portion of its fully underwritten 1-for-5.4 accelerated non-renounceable entitlement offer to raise about AU$1.5 billion in total, according to a Monday filing with the Australian bourse.The retail offer, expected to raise around AU$500 million, is priced at AU$12.70 apiece, the same price used in the institutional component, which recently closed and raised about AU$1 billion, per the filing.Eligible retail shareholders who fully exercise their entitlement may also apply for additional new shares up to 100% of their entitlement at the offer price under the top-up facility, the filing added.

$ASX:NXT